Loading
A phase 3 trial of Datopotamab deruxtecan, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Daiichi Sankyo, active and no longer recruiting.
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations. ClinicalTrials.gov record last updated 2026-09-24: active not recruiting. Enrollment is actual at 740 participants. Primary completion is estimated at 2030-03-04. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Datopotamab Deruxtecan, Pembrolizumab. Registered primary measures: Progression-free Survival Based on Blinded Independent Central Review in Participants With Non-Squamous Histology Who Were Administered Dato-DXd in Combination With Pembrolizumab Compared With Pembrolizumab; Overall Survival (OS) in Participants With Non-Squamous Histology Who Were Administered Dato-DXd in Combination With Pembrolizumab Compared With Pembrolizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Daiichi Sankyo, Small-cell lung cancer, Pembrolizumab.
Shares Datopotamab deruxtecan, PD-L1-high non-small-cell lung cancer without a driver mutation, TROP2, Small-cell lung cancer.
Shares Datopotamab deruxtecan, Daiichi Sankyo, TROP2, Small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, TROP2, Small-cell lung cancer, Pembrolizumab.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/